US-based early-stage pharmaceutical company EydisBio announced on Wednesday that the US National Institute of Health's (NIH) National Heart, Lung, and Blood Institute (NHLBI) has provided a USD2.6m Phase two Small Business Innovation Research (SBIR) grant to the company.
The grant is intended to support the company's ongoing research into the efficacy of TAK1 inhibition in animal models of systemic sclerosis, and declare a lead compound for progression into the clinic.
Dr Tim Haystead, EydisBio founder and president, said, 'We are honoured to receive this significant grant from the NHLBI. This funding will enable us to continue to advance our TAK1 inhibitor program in systemic sclerosis and bring us closer to developing a new therapeutic option for these patients. We are strongly committed to improving the lives of those affected by this debilitating disease.'
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults